14.05
price down icon2.43%   -0.35
after-market  After Hours:  14.03  -0.02   -0.14%
loading
Novavax, Inc. stock is currently priced at $14.05, with a 24-hour trading volume of 9.36M. It has seen a -2.43% decreased in the last 24 hours and a +7.99% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $14.26 pivot point. If it approaches the $13.64 support level, significant changes may occur.
Previous Close:
$14.40
Open:
$14.34
24h Volume:
9.36M
Market Cap:
$2.07B
Revenue:
$693.46M
Net Income/Loss:
$-545.06M
P/E Ratio:
-1.9353
EPS:
-7.26
Net Cash Flow:
$-772.77M
1W Performance:
-12.21%
1M Performance:
+7.99%
6M Performance:
+160.19%
1Y Performance:
+74.75%
1D Range:
Value
$13.85
$14.78
52W Range:
Value
$3.5324
$23.86

Novavax, Inc. Stock (NVAX) Company Profile

Name
Name
Novavax, Inc.
Name
Phone
240-268-2000
Name
Address
20 Firstfield Road, Gaithersburg, MD
Name
Employee
362
Name
Twitter
@novavax
Name
Next Earnings Date
2024-06-13
Name
Latest SEC Filings
Name
NVAX's Discussions on Twitter

Novavax, Inc. Stock (NVAX) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-09-23 Upgrade B. Riley Securities Neutral → Buy
Apr-20-23 Downgrade TD Cowen Outperform → Market Perform
Mar-01-23 Downgrade B. Riley Securities Buy → Neutral
Jan-09-23 Reiterated B. Riley Securities Buy
Dec-30-22 Reiterated H.C. Wainwright Buy
Dec-02-22 Initiated Jefferies Hold
Sep-22-22 Downgrade JP Morgan Neutral → Underweight
May-20-22 Initiated BofA Securities Underperform
Feb-23-22 Reiterated B. Riley Securities Buy
Feb-22-22 Resumed Jefferies Buy
Jan-21-22 Initiated Cowen Outperform
May-12-21 Downgrade JP Morgan Overweight → Neutral
Dec-14-20 Initiated Jefferies Buy
Aug-06-20 Reiterated H.C. Wainwright Buy
Aug-05-20 Upgrade JP Morgan Neutral → Overweight
Aug-05-20 Downgrade Ladenburg Thalmann Neutral → Sell
Jul-16-20 Reiterated H.C. Wainwright Buy
Jul-08-20 Downgrade Ladenburg Thalmann Buy → Neutral
Jun-29-20 Reiterated B. Riley FBR Buy
Jun-29-20 Reiterated H.C. Wainwright Buy
Jun-05-20 Upgrade JP Morgan Underweight → Neutral
May-28-20 Reiterated B. Riley FBR Buy
May-12-20 Reiterated H.C. Wainwright Buy
Apr-30-20 Reiterated H.C. Wainwright Buy
Nov-27-19 Resumed B. Riley FBR Buy
Aug-14-19 Reiterated H.C. Wainwright Buy
Feb-28-19 Downgrade Piper Jaffray Overweight → Underweight
Dec-18-18 Initiated Ladenburg Thalmann Buy
Dec-11-18 Initiated Oppenheimer Outperform
Nov-26-18 Upgrade Piper Jaffray Neutral → Overweight
Sep-21-18 Upgrade JP Morgan Underweight → Overweight
Mar-29-18 Upgrade Seaport Global Securities Neutral → Buy
View All

Novavax, Inc. Stock (NVAX) Financials Data

Novavax, Inc. (NVAX) Revenue 2024

NVAX reported a revenue (TTM) of $693.46 million for the quarter ending December 31, 2023, a -59.37% decline year-over-year.
loading

Novavax, Inc. (NVAX) Net Income 2024

NVAX net income (TTM) was -$545.06 million for the quarter ending December 31, 2023, a +17.16% increase year-over-year.
loading

Novavax, Inc. (NVAX) Cash Flow 2024

NVAX recorded a free cash flow (TTM) of -$772.77 million for the quarter ending December 31, 2023, a -51.85% decrease year-over-year.
loading

Novavax, Inc. (NVAX) Earnings per Share 2024

NVAX earnings per share (TTM) was -$5.56 for the quarter ending December 31, 2023, a +33.81% growth year-over-year.
loading
Novavax, Inc., together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen. The company develops respiratory syncytial (RSV) virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III clinical trial; older adults in Phase II clinical trial; and children six months to five years of age in Phase I clinical trial. Novavax, Inc. also develops NanoFlu vaccine, which is in Phase I/II clinical trial for treating seasonal influenza in older adults; and Ebola virus glycoprotein vaccine that is in Phase I clinical trial. Its preclinical programs include Zika virus; combination respiratory vaccine candidate to protect against RSV and seasonal influenza, as well as other infectious disease vaccine candidates. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
$85.02
price up icon 1.81%
$25.78
price down icon 1.57%
$159.38
price down icon 1.97%
$157.30
price down icon 1.93%
$88.44
price down icon 3.95%
$378.30
price down icon 2.25%
Cap:     |  Volume (24h):